In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (01/07)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups are "Treating Traumatic Brain Injury," with profiles of Banyan Biomarkers, NeuroPharma AB, and RemeGenix; and "Can Stents Pull Off a Disappearing Act?," with profiles of Amaranth Medical, Bioabsorbable Therapeutics, and TissueGen Plus these Start-Ups Across Health Care: Design Medical, Kythera Biopharmaceuticals and Plethora Solutions.

You may also be interested in...



Amaranth Medical Inc.

With technology developed at Nanyang Technological University. Amaranth has entered into an increasingly competitive race involving start-ups with their eyes on a considerable prize-the creation of a vascular stent composed of biodegradable polymers.

Bioabsorbable Therapeutics Inc.

Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.

TissueGen Inc.

TissueGen, a start-up spun out of the University of Texas, is developing a bioabsorbable stent that permits the delivery of hydrophilic, or water soluable, therapeutics. If successful the sent would open up the door for a whole new family of drugs to be delivered via a stent.

Related Content

Related Companies

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel